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Mitomycin C measurement in tumor tissue
in vitro and in vivo
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Abstract
Two methods of quantifying Mitomycin C in tumor tissue are explored. A method of ultraviolet-visible absorption
microscopy is developed and applied to measure the concentration of Mitomycin C in preserved mouse tumor tissue,
as well as in gelatin samples. Concentrations as low as 60 μM can be resolved using this technique in samples that do
not strongly scatter light. A novel method for monitoring the Mitomycin C concentrations inside a tumor is developed,
based on microdialysis and ultraviolet-visible spectroscopy. A pump is used to perfuse a microdialysis probe with
Ringer’s solution, which is fed to a flow cell to determine intratumor concentrations in real time to within a few μM.
The success and limitations of these techniques are identified, and suggestions are made as to further development.
To the authors’ knowledge these are the first attempts made to quantify Mitomycin C concentrations in tumor tissue.
Background
Bladder cancer is the seventh most common cancer in
men. In 2008, approximately 386 300 cases were diag-
nosed and 150 200 patients died of the disease worldwide
[1]. Approximately 70% of bladder tumors are superfi-
cial (not muscle invasive) at the moment of diagnosis.
This includes Ta tumors, limited to the mucosa; carci-
noma in situ, flat lesions limited to the mucosa with high
risk of progression; and T1 tumors, invading the con-
nective tissue (lamina propria) immediately under the
mucosa. Patients with Ta tumors are treated with surgi-
cal resection (TURBT) followed by intravesical instillation
with the chemotherapeuticMitomycin C (MMC, approxi-
mately 2.4 mM) to kill remnant tumor cells in the bladder.
Mitomycin C diffuses mainly into the mucosa but poorly
deeper into lamina propria during intravesical therapy,
and this may explain why MMC has poor efficacy treat-
ing tumors growing deeper in the bladder wall than Ta
tumors.
Electroporation (EP) is a physical method in which
short electric pulses are used to increase the permeability
of the cell membrane, thereby allowing the introduction
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of molecules (e.g. drugs or genes) into the cytoplasm.
It is the basis of electrochemotherapy, where uptake of
chemotherapeutics is enhanced and their effect improved
[2]. This modality is efficiently used in vivo for the treat-
ment of cutaneous and subcutaneous tumors [3-6] and
is now being introduced for the treatment of internal
tumors [7-10]. A recent study investigated the cytotox-
icity of the combination of EP and MMC on a bladder
cancer cell line showing additive effect with an increase
of 30% in cytotoxicity [11]. Data have shown that the
combination of EP and MMC is more effective and abid-
ing than MMC alone on the nude mice tumor model
using a bladder cancer cell line [12]. It remains to be
shown whether the intracellular concentration of MMC
actually increases with EP, or whether the additive effect
is due to the combined toxic effects of electric pulses
and MMC.
Di Stasi et al. suggested that the application of elec-
tric current during the administration of MMC would
improve the transport of the drug through the urothe-
lium into the deeper layers of the bladder wall [13]. In that
ex-vivo study, the bladder specimens were homogenized
followed by HPLC analysis to obtain concentration-depth
profiles. While functional, this method does not provide
© 2013 Fischer et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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a clear picture of how the drug is penetrating the various
tissue layers in the bladder wall.
The aim of this work is to develop methods for the
detection and quantification of MMC directly in tissue, so
it can be used in further studies. We used the nude mouse
animal model aiming to measure MMC within tumors
during treatment with MMC, quantify MMC uptake into
tumor cells, and monitor the chemical contents of the
tumor in real-time, as well as post-treatment inspection
of mounted tumor samples. In the first effort, a novel
method of UV-Vis absorption microscopy was employed
in an attempt to directly map the concentration profile of
the MMC within the tumor. This consists not only of the
development of the imagingmethod itself, but also a num-
ber of adjustments to the sample preparation protocol.
In the second effort, a form of on-line UV-Vis absorp-
tion spectroscopy fed by a microdialysis probe is used to
directly monitor the internal contents of a mouse tumor
during the MMC treatment. More accurate measure-
ment of the pharmacokinetics may facilitate a mechanistic
understanding of this treatment, potentially improving it
to become a minimally invasive alternative to cystectomy
(removal of the bladder) for patients with bladder tumors
that invade the lamina propria (T1).
Results and discussion
UV-Vis Absorption microscopy
MMC Imaging Proof-of-concept
Initial imaging was performed on samples of gelatin
spiked with MMC as a proof-of-concept. Samples of 100
μm thick gelatin slabs (5% w/v in water) with 0 μM, 60
μM, and 180 μMMMCwere imaged, shown in Figure 1a.
The gelatin samples were optically clear to the eye, but
the difference in MMC concentration could be correctly
calculated through image analysis. The calculated MMC
concentrations depended linearly on the added concen-
trations as expected (data not shown), but required a
calibration factor. Concentration variations across the
micrographs in Figure 1a are ascribed to inhomogeneous
sample illumination. Following the gelatin samples, drops
of phosphate buffered saline containing 0 μM, 100 μM,
and 500 μM were placed on a microscope slide and dried
in a vacuum desiccator. This caused salt crystals to form
in place of the saline drops, with solid MMC mixed in
with the salt. Figure 1b shows that sharp discontinu-
ities in refractive index (at the air/solid interfaces) in the
dried medium lead to scattering which manifests as an
apparent absorption. Despite the artifacts at the crystal
edges, higher concentration of MMC are clearly observed
within the crystals in the image of 500 μM concen-
tration. These proof-of-concept images confirmed that
the microscope setup, acquisition software, and image
processing code could adequately image MMC in thin
sample volumes.
Paraffin-embedded tumor samples
Imaging attempts were next made on paraffin-embedded
mouse tumors. Slices of thicknesses 100 μm and 50 μm
were found to have too high absorbance for the analy-
sis setup, in agreement with the tumor samples having
a white appearance due to strong light scattering. Best
results were obtained with 10 μm thick tumor samples,
while usable but non-optimal results were observed with
20 μm thick samples. Figure 2 presents representative
images of tumor sample slices without or withMMC treat-
ment prior to removal. In contrast to images with thicker
samples (20-100μm), the images acquired for 10μm thick
samples are highly reproducible thanks to improvements
made to the image processing code and microscope setup,
as explained in the Methods section. Unfortunately there
was no measurable difference between the treated and
untreated tumors in terms of MMC concentration. Scat-
tering can be seen from the tissue matrix, but no parts of
the samples display increased levels of MMC.
Freeze-dried tumor samples
Following removal from the mouse, the tumor is im-
mersed in a series of ethanol/water baths of increas-
ing ethanol concentration to dehydrate the tissue, before
being embedded in paraffin wax. Since MMC is highly
soluble in both water and ethanol at the injected concen-
tration (5 mM), we suspected that the MMC was being
removed during this dehydration procedure. Thus, the
sample preparation procedure was altered to eliminate
solvent-induced dehydration. Subsequent samples were
placed in liquid nitrogen immediately following removal
from themouse, and sectioned and stored at temperatures
below -20°C until freeze-drying.
The freeze-drying process used frozen tumor slices
attached by immersion oil to a glass slide, and was very
effective at removing all water from the tissue samples.
However, this process proved to be too mechanically
stressful for the tissue samples, as several were dam-
aged by the partial evaporation of the immersion oil
under vacuum conditions (results not shown). Addition-
ally, Figure 3 shows that there is no discernible difference
between untreated (Figure 3a), treated (Figure 3b), and
electroporation-treated (Figure 3c) samples. These same
samples were spiked with 500 μM MMC, dried, and re-
imaged (Figure 3d). Even when large amounts of MMC
were added to the sample, we observed very low concen-
trations in the calculated concentration micrographs.
An optimized procedure used vacuum-compatible sil-
icone oil instead of vacuum-incompatible immersion oil
for mounting the samples, and the samples were further
positioned so that contact between the tumor slice and the
mounting oil was avoided. The freeze-drying process was
once again highly effective, but the tissue became a net-
work of solid fibers. Since all areas of the sample were now
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Figure 1 Concentration micrographs of MMC in gelatin and in dried state. a)Mitomycin C was dissolved in aqueous gelatin at concentrations
of 0, 60, and 180 μM to form thin hydrogel slices, that were imaged at the detection and reference wavelengths, respectively. The resulting images
were used for computing the displayed concentration micrographs. b) Droplets of MMC were placed on a glass slide at the nominal concentrations
and allowed to dry. Crystallite boundaries scatter light and appear as high MMC concentrations in the micrograph. The color scale shows the MMC
concentrations at specific locations. The difference in units (μM and mM) in the two color scales should be noted.
Figure 2 Concentration micrographs of wax-embedded tumor samples. Concentration micrographs of 10 μm thick tumor samples
embedded in paraffin wax after a) not being treated, and b) being treated with a 5 mMMMC injection before removal. The white line denotes the
outer boundary of the tissue area, while the color map indicates the concentration of MMC at specific locations. Since only 5 mMMMC was injected,
any concentrations higher than this are purely artifacts caused by light scattering.
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Figure 3 Concentration micrographs of freeze-dried tumor samples. Concentration micrographs of 10 μm thick tumor samples frozen after
removal and freeze-dried. The figure depicts samples that have a) not been treated, b) been treated with MMC, c) been treated with MMC and had
electroporation performed, and d) have been spiked with MMC after freeze-drying. The white line denotes the outer boundary of the tissue area.
either air gaps or fully opaque solid material, light absorp-
tion by MMC could not be detected on any sample area
(data not shown).
Microdialysis
Probe installation
The tumors were found to be extremely dense, making
installation of the probe difficult. A 1.2 mm needle was
used to produce a hole in the tumor for the guide cannula
to fit, into which the probe was inserted.
Real-timemonitoring of tumor contents
Following calibration and installation of the probe, the
effect of injected MMC was observed. Figure 4a is a rep-
resentative plot of the evolution of the MMC and blood
signals during the experiment. Responses in the absorp-
tion signals were reproducibly and expectedly observed
with a delay of 4-5 min after a given manipulation of the
tumor due to the time required for the probe dialysate
to reach the detection cell. The blue line represents
the relative concentration of the MMC, while the red
line represents that of the blood. Two observations are
immediately obvious from this plot. First, the blood sig-
nal rises with the injection of MMC. While MMC has
absorption components overlapping the blood absorp-
tion, this accounts for only 10% of the observed increase
in the blood signal. We hypothesize that the manipula-
tion of the tumor and the increased intratumoral pres-
sure during injection forces fresh blood or extracellular
fluid to the probe site where blood or fluid components
are taken up by the probe, followed by an associated
spike in this signal and a slow decline as equilibrium
returns.
Second, no MMC concentration spike is observed after
the third injection. Subsequent trials and tumor dissec-
tions led us to believe that the first injection creates the
greatest pressure within the tumor, and thus opens paths
in the tumor for injected volumes to escape. This results
in subsequent injections passing out of the tumor with-
out enough pressure being developed for liquid transport
to the probe site. This was observed for every experiment
when multiple injections were made (data not shown);
thus the experiment was adapted to include only a single
injection of MMC.
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Figure 4 Real-timemonitoring of intratumor MMC via microdialysis. All plots show the evolution of the magnitude of the MMC (blue line) and
blood absorption (red line). There is a latency time of 4-5 min from the tissue fluid is sampled till it reaches the detector. In a) the probe is installed
and the tumor is injected with MMC three times with and without electroporation (EP). In b) a second EP treatment is performed after the initial
treatment, and a small MMC signal is observed, despite no additional MMC being injected. In c) an EP treatment without an MMC injection shows
that EP alone does not produce an MMC signal. Plot d) shows an EP treatment without MMC injection, as well as the probes being placed on the
tumor without application of voltage pulses. This shows that it is the physical manipulation of the tumor that is transferring MMC within the tumor,
and that the measured MMC signal is unrelated to EP.
As shown in Figure 4b, a second spike in MMC concen-
tration can be produced by applying an electroporation
treatment sometime after the MMC injection. Figure 4c
confirms that this is not some artifact of the EP treatment;
such treatment before the MMC injection results only in
a blood absorption spike. Thus, the MMC contributing to
the increased signal seen in Figure 4b can only have come
from the injected volume itself. The remaining question
was: where was this MMC stored between the time of
injection and when it reappeared? Figure 4d suggests that
the MMC collects in extracellular space within the tumor,
as well as the space between the tumor and skin, since
the MMC concentration can be altered by merely placing
the electrodes on the tumor, i.e, even without applying EP
voltage pulses. Thus, we find that any physical handling
of the tumor causes enough internal pressure to rearrange
the chemical contents of the tumor.
Conclusions
This work has for the first time demonstrated two novel
methods of quantifying MMC in tumor tissue, both of
which have shown promise. Real-time monitoring of
tumor contents via a microdialysis probe continuously
feeding a UV-Vis flow cell was able to measure MMC
over the span of several hours with a sampling interval
of less than a minute. In this particular application, the
chemotherapeutic was injected directly into the tumor.
The method was able to identify approximate intratumor
concentrations, but lacked the sensitivity to determine any
additional amount of MMC that may have entered the
tumor cells under the application of EP. Nonetheless, this
method proved to be a simple and compact method for
continuous monitoring of specific tumor contents. Abso-
lute concentration measurements in internal volumes will
additionally require an in vivo calibration that was not
explored in this work.
Absorption microscopy has shown promising results
when imaging liquid or gelatin samples containing Mit-
omycin C at concentrations as low as 60 μM. However,
when attempting to apply the technique to tumor tissue
samples, a number of problems were encountered. Tumor
tissue can be very optically dense, calling for a sample
thickness of 10 μm thick or less, and even then every opti-
cal interface scatters light quite strongly. The dehydration
process normally used to preserve tissue samples is likely
to wash away any MMC, leaving none to be measured.
Freeze-drying was employed to remove the possibility
of MMC-loss during typical dehydration procedures, but
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proved to leave the samples in a state where MMC could
not be imaged at all. Our conclusion from this work is
that imaging MMC in preserved tissue is extremely dif-
ficult. Since the only really successful imaging of MMC
occurred in aqueous solution, we suggest future efforts to
be directed towards imaging planar cell cultures, and live,
wet tissue samples.
Methods
UV-Vis Absorption Microscopy
Ultraviolet-visible spectroscopy (UV-Vis) measures the
intensity of light that passes through a sample, I1, com-
pared to the incident light intensity, I0. If the absorbance of
light is solely due to molecular absorption, the measured
absorbance, A, is related to the total compound concen-
tration at every wavelength, λ, by the Beer-Lambert Law
(Equation 1):
Aλ = log
[ I0
I1
]
= λ · c · L (1)
Thus, if one knows the molar extinction coefficient, λ,
(determined empirically or found in literature), and the
optical path length, L, one can easily determine the con-
centration, c, of the substance being examined. Figure 5a
depicts the absorption spectrum of MMC.
Absorption microscopy works on the same principle as
UV-Vis spectroscopy, but instead the concentration calcu-
lations are made for every pixel in an image. Certain bands
of wavelengths are selected by using optical filters (as
seen in Figure 5a), specifically chosen to match the peak
absorption (filter A) and background absorption (filter B)
when measuring MMC. Since absorption is additive, one
can subtract the background absorption (filter B) from the
peak absorption (filter A), to obtain the absorption contri-
butions for MMC alone at each pixel in an image. Spatial
mapping of concentration variations by optical absorption
microscopy has been explored by Van Noorden et al. for
quantifying enzymatic activity in rat liver tissue [14,15]
with detailed descriptions of the methodology presented
in a recent extensive review [16].
Referring to Equation 1 and the assumption of light
absorbance being only caused by molecular absorption
by the analyte of interest, this technique must balance
two competing effects. First, a thicker sample (larger L)
will allow more light to be absorbed at a given ana-
lyte concentration, thus allowing smaller concentrations
to be detected. Second, thinner samples will place fewer
structural artifacts (tumor cells, muscle, connective tis-
sue) in the optical path, thus scattering less light. Light
scattering on microscale features of tissue is governed
by a combination of Mie and Rayleigh scattering, occurs
at all wavelengths, and cannot be compensated or mod-
eled. The light lost will appear as an apparent absorption
and reduce the accuracy of our measurements. Thus, this
technique must strike a balance between these effects
to minimize scattering by artifacts (thinner samples) and
maximize analyte absorption (thicker samples) to obtain
accurate and reliable concentration micrographs. Addi-
tionally, the peak absorbance and background absorbance
signals should be measured at the smallest useful sepa-
ration in wavelength to minimize differential (wavelength
dependent) light scattering between these two signals.
Absorption microscopy evaluation samples were pre-
pared using gelatin (porcine skin, cat. no. G1890, Sigma-
Aldrich, St. Louis,MO), phosphate buffered saline (Lonza,
Basel, Switzerland), and MMC (Medac GmbH, Hamburg,
Germany). Biopsy and tumor preparation was performed
at Copenhagen University Hospital Herlev. Tumors were
treated with MMC in vivo and then excised and dehy-
drated via subsequent immersions in solutions of 70%
v/v, 96% v/v, and 99% v/v ethanol/water, respectively,
and embedded in paraffin blocks. In the case of the
freeze-dried samples, tumors were treated in vivo, excised,
and immediately placed in liquid nitrogen, before being
embedded in Tissue-Tek® O.C.T™ Compound (Sakura,
Alphen aan der Rijn, The Netherlands). Slices of paraffin
or epoxy embedded samples were received on glass micro-
scope slides, with the frozen samples needing to be placed
on immersion oil or silicone oil since frozen slices will oth-
erwise not stick to cooled glass slides. Two image sets were
captured for each sample, one for the peak absorption
(filter A, 365 nm bandpass) and one for the background
absorption (filter B, 436 nm bandpass). Images were pro-
cessed and evaluated by a custom MATLAB script with
Equation 2 at its core:
C = 1
365nm · L (A365nm − A436nm) (2)
where C is the matrix of concentration values across
the image (i.e. pixels), the absorbance matrices Aλ are
described by Equation 1, and 365nm and L are scalar val-
ues as in Equation 1 as well. The raw recorded images were
additionally compensated for spatial variations in illumi-
nation intensity and effects of lens vignetting of the image
projected onto the camera CCD chip, differences in CCD
light sensitivities at the two wavelengths used, as well as
dark noise of the CCD chip. The compensation procedure
used images at the two wavelengths recorded without a
sample in the light pathway, and with and without illu-
mination light turned on. The resulting concentration
micrographs are displayed as a color map to represent the
presence of MMC.
Figure 5b shows a schematic of the microscope setup
for imaging MMC in tissue samples. The apertures
added on both sides of the sample plane function as
light collimators that significantly reduce the collection
of scattered stray light. An Axiovert 100M microscope
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Figure 5MMC absorption spectrum and absorption microscopy setup. a) Plot of the UV-Vis absorption spectrum of MMC, with highlighting of
the transmission range of the filters used in imaging. b) Schematic of the UV-Vis microscopy setup, including placement of sample, filters, and
apertures.
(Carl Zeiss, Oberkochen, Germany) with an iXon digi-
tal camera (Andor Technology, Belfast, UK) was used for
transmission imaging, illuminated by a 100 W halogen
light source. Bandpass filters for 365 nm (filter A, band
width 12 nm, model no. 365/12 BP) and 436 nm (filter B,
band width 10 nm, model no. 436/10 BP) were used as
received from DELTA (Hørsholm, Denmark). A custom
machined stage and apertures were used, as was a custom
made LabView program for controlling the microscope
and the camera.
Microdialysis
A microdialysis probe works on the same principles as
the Loop of Henle in the kidney. A carrier liquid, the per-
fusate, is perfused into the probe. This fluid travels to the
probe tip and passes over the dialysis membrane. This
membrane, which is in contact with the environment,
allows chemical species (below a molecular weight of 10
kDa) to pass freely. The fluid, now called the dialysate,
leaves the probe and travels to the measurement device.
The construction of a microdialysis probe can be seen
in Figure 6c. Since there is no convective transfer of
fluid between the probe and the environment, this type
of probe is particularly useful when measuring in small
confined volumes or in vivo, for examplemonitoring accu-
mulation of chemotherapeutics in breast tissue [17,18]. A
typical dialysate sample is collected over 20-30 minutes
(to accumulate a minimum volume) and analyzed using
HPLC [19], capillary electrophoresis [17], or immunoas-
say methods [18]. For an overview of this technique please
refer to the article by Chauruasia et al. [20].
The amount of chemical compound returned to the
measurement system is a function of the pumping speed,
probe environment, probe geometry, and properties of
the compound itself. The concentration measured in the
dialysate, under relatively steady-state conditions, can be
simply expressed as a percentage of the chemical con-
centration in the probe’s immediate environment; this is
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Figure 6Microdialysis setup and operation. a) Ringer’s solution is perfused into the MD probe, and the sample is passed to a flow cell being
continuously analyzed by a UV-Vis spectrometer. Absorption data is recorded and the dialysate continues to the waste container. b) The probe is
inserted into the subcutaneous tumor on the mouse and fixed with surgical tape. c) The tip of the probe has Ringer’s solution continually flowing at
a rate of 2 μl/min, allowing small molecules (e.g.MMC) to pass into the dialysate and be carried to the flow cell for analysis.
called the extraction coefficient, and is determined exper-
imentally via a calibration procedure before, during, or
after the experiment. In the work presented here, an
in vitro calibration was performed for every microdialysis
probe used, not only to assess the extraction coefficient,
but also to ensure that the probe was working within
acceptable tolerances. The graphs showing in vivo con-
centrations over time are stated in absorbance units (AU)
because no in vivo calibrations could be made during the
time the probe was functional and installed in the mouse
tumor. As as estimate of concentrations measured, in vitro
calibration yielded 4± 1× 102 μM/AU, tested for five dif-
ferent probes, and absorption resolution was better than
0.01 AU.
A schematic of the equipment configuration used for
this experiment can be seen in Figure 6a. Microdialysis
probes used in this experiment were type-AZ stainless
steel, 4 mmmembrane length (artificial cellulose) (cat. no.
AZ-8-04, Eicom Corp., Kyoto, Japan), and are intended
for use in rat brains. Perfusion of Ringer’s solution into
the probe was accomplished with a single programmable
syringe pump (New Era Pump Systems, Farminglade,
NY, model no. NE-1000). The probe dialysate was fed
into a fiber-optic micro-flow cell from World Precision
Instruments (Sarasota, FL, model no. LWCC-M-10),
with an optical path length of 10 mm accessed via
quartz windows. An AvaSpec-3648 UV-Vis spectrome-
ter using an AvaLight-DH-S-BAL combined deuterium-
halogen light source (both from Avantes, Apeldoorn,
The Netherlands) was connected to a laptop to acquire
spectra and monitor specific wavelengths throughout the
experiment. The spectrometer and light source were con-
nected to the flow cell using 600 μm core diameter,
solarization-resistant optical fibers (1 m length, model no.
QP600-1-SR-BX, Ocean Optics, Dunedin, FL).
In vivo experiments were conducted according to
European Convention for the Protection of Vertebrate
Animals used for Experimentation and with approval from
the Danish Animal Experimentation Inspectorate. SW780
human bladder cancer cells were tested by rapid MAP27
panel (Taconic, Hudson, NY) without signs of infection.
Cells were grown in DMEM culture medium (Gibco, Life
Technologies, Carlsbad, CA), 10% fetal calf serum (Gibco,
Life Technologies), penicillin, and streptomycin at 37°C
and 5% CO2. After harvesting cells, a total of 1 × 106
cells per ml diluted in PBS were injected subcutaneously
on the left flank of 9 - 11 week-old NMRI-Fox1nu mice
(own breeding). Tumor volume was calculated as a b2 π/6
(a, largest diameter; b, largest diameter perpendicular
to a). At an average tumor volume of 100 mm3, the mice
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were selected for the experiments. Hypnorm-dormicum
(VetaPharma, Leeds, UK and Roche, Basel, Switzerland)
was used for anesthesia complemented with rimadyl
(Pfizer, NewYork City, NY). Themice were fixed with tape
and intratumoral injections were performed with MMC
at different concentrations, with volumes equivalent to
the tumor volume. MMC was previously diluted to the
desired concentration with isotonic saline. EP was per-
formed using a 6 mm plate electrode and a square wave
electroporator (Cliniporator, IGEA, Frankfurt, Germany).
EP parameters were: 8 pulses of 100 μs at 1.0 kV/cm and
1 Hz. Once the experiment was finished, the mouse was
sacrificed. Figure 6b depicts the anesthetized mouse with
a microdialysis probe installed.
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